{
    "root": "3631d351-4653-3512-e063-6394a90a81c0",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Deferiprone",
    "value": "20250528",
    "ingredients": [
        {
            "name": "CROSPOVIDONE, UNSPECIFIED",
            "code": "2S7830E561"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "METHYLCELLULOSE (15 MPA.S)",
            "code": "NPU9M2E6L8"
        },
        {
            "name": "COPOVIDONE K25-31",
            "code": "D9C330MD8B"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "MEDIUM-CHAIN TRIGLYCERIDES",
            "code": "C9H2L21V7U"
        },
        {
            "name": "POLYDEXTROSE",
            "code": "VH2XOU12IE"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "DEFERIPRONE",
            "code": "2BTY8KH53L"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        }
    ],
    "indications": "deferiprone tablets indicated treatment transfusional iron overload adult patients thalassemia syndromes current chelation therapy inadequate .",
    "contraindications": "deferiprone tablets available two formulations . 1,000 mg formulation 500 mg formulation , different dosing regimens achieve total daily . ( 2.1 ) prevent medication errors , prescribing dispensing , ensure tablet formulation appropriate dosing regimen . tablet distinct identifying characteristics . ( 2.1 , 3 ) deferiprone tablets ( three times day ) , 1,000 mg : starting oral : 75 mg/kg/day ( actual body weight ) three divided doses ( 2.3 ) maximum oral : 99 mg/kg/day ( actual body weight ) three divided doses ( 2.3 ) deferiprone tablets ( three times day ) , 500 mg : starting oral : 75 mg/kg/day ( actual body weight ) three divided doses ( 2.4 ) maximum oral : 99 mg/kg/day ( actual body weight ) three divided doses ( 2.4 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "deferiprone contraindicated patients known hypersensitivity deferiprone excipients formulations . following reported association deferiprone : henoch-schönlein purpura ; urticaria ; periorbital edema skin rash [ ( 6.2 ) ] .",
    "indications_original": "Deferiprone tablets are indicated for the treatment of transfusional iron overload in adult patients with thalassemia syndromes when current chelation therapy is inadequate.",
    "contraindications_original": "Deferiprone tablets are available in two formulations. A 1,000 mg formulation and a 500 mg formulation, which have different dosing regimens to achieve the same total daily dosage. ( 2.1 ) To prevent medication errors, before prescribing and dispensing, ensure that the tablet formulation is appropriate for the dosing regimen. Each tablet has distinct identifying characteristics. ( 2.1 , 3 ) Deferiprone tablets (three times a day), 1,000 mg: Starting oral dosage: 75 mg/kg/day (actual body weight) in three divided doses ( 2.3 ) Maximum oral dosage: 99 mg/kg/day (actual body weight) in three divided doses ( 2.3 ) Deferiprone tablets (three times a day), 500 mg: Starting oral dosage: 75 mg/kg/day (actual body weight) in three divided doses ( 2.4 ) Maximum oral dosage: 99 mg/kg/day (actual body weight) in three divided doses ( 2.4 )",
    "adverseReactions_original": "Deferiprone is contraindicated in patients with known hypersensitivity to deferiprone or to any of the excipients in the formulations. The following reactions have been reported in association with the administration of deferiprone: Henoch-Schönlein purpura; urticaria; and periorbital edema with skin rash\n \n  [see\n  \n   Adverse Reactions (6.2)]."
}